Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 10.75 USD 3.56% Market Closed
Market Cap: 91.6m USD

Wall Street
Price Targets

STRO Price Targets Summary
Sutro Biopharma Inc

Wall Street analysts forecast STRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STRO is 35.99 USD with a low forecast of 8.08 USD and a high forecast of 105 USD.

Lowest
Price Target
8.08 USD
25% Downside
Average
Price Target
35.99 USD
235% Upside
Highest
Price Target
105 USD
877% Upside
Sutro Biopharma Inc Competitors:
Price Targets
UTHR
United Therapeutics Corp
1% Upside
EDT
Spectral Medical Inc
149% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
48% Upside
SNDX
Syndax Pharmaceuticals Inc
86% Upside
CCCC
C4 Therapeutics Inc
446% Upside
INCY
Incyte Corp
1% Upside
TWST
Twist Bioscience Corp
18% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
34% Upside

Revenue
Forecast

Revenue Estimate
Sutro Biopharma Inc

For the last 7 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 3%. The projected CAGR for the next 4 years is -8%.

3%
Past Growth
-8%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STRO's stock price target?
Price Target
35.99 USD

According to Wall Street analysts, the average 1-year price target for STRO is 35.99 USD with a low forecast of 8.08 USD and a high forecast of 105 USD.

What is Sutro Biopharma Inc's Revenue forecast?
Projected CAGR
-8%

For the last 7 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 3%. The projected CAGR for the next 4 years is -8%.

Back to Top